title: In vivo biological effects of foam sclerotherapy.
abstract: OBJECTIVE
  This study aims to assess by biological markers the in vivo consequences of foam sclerotherapy (FS) of saphenous veins. The secondary objective of this randomised controlled trial (RCT) is to compare results of two randomised groups: with or without post-treatment compression.
  
  
  METHODS
  Forty patients with incompetent great or small saphenous veins underwent ultrasound-guided FS. Randomisation was conducted immediately after sclerotherapy to two parallel groups, one (CG) with compression stockings and the other (WCG) without compression. A laboratory work-up was done on days 0 (before sclerotherapy), 1, 7, 14 and 28. The studied markers were: fibrinogen, factor VIII, thrombomodulin, thrombin-antithrombin complex, D-dimers, platelet factor 4 and troponin.
  
  
  RESULTS
  General data repartition was homogenous for CG and WCG. Twenty patients were included in each group (females 90%; mean age 58 years). On day 28 (D28), the occlusion rate of the veins was 100% in both groups. In all the samples (D0-D28), apart from a moderate D-dimers' increase at D1-D14, no significant biological change was observed in either the WCG or the CG groups.
  
  
  CONCLUSIONS
  In terms of inflammation and coagulation, FS seems to have a minimal effect on peripheral blood, either with or without post-treatment compression and does not appear to have an effect on the myocardial risk.
authors.affiliation: Saint Martin Private Hospital, Department of Vascular Medicine, 18 rue des Roquemonts, 14050 Caen, France. claudine@desnos.eu
authors.forename: C M
authors.initials: CM
authors.lastname: Hamel-Desnos
authors.forename: P R
authors.initials: PR
authors.lastname: Desnos
authors.forename: B
authors.initials: B
authors.lastname: Ferre
authors.forename: A
authors.initials: A
authors.lastname: Le Querrec
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D005260:Female; D005602:France; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012501:Saphenous Vein; D012597:Sclerosing Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000009:adverse effects; D053828:Stockings, Compression; D013997:Time Factors; D016896:Treatment Outcome; D014689:Venous Insufficiency / Q000097:blood / Q000628:therapy*
chemical_list: D015415:Biomarkers; D018836:Inflammation Mediators; D012597:Sclerosing Solutions